Sanofi: Sarclisa approved for multiple myeloma in China

(CercleFinance.com) - Sanofi reports that the Chinese NMPA has approved its Sarclisa, in combination with pomalidomide and dexamethasone (Pd regimen) for the treatment of relapsed or refractory multiple myeloma in adults who have received at least one prior treatment.


This approval is prompted by the results of studies demonstrating that Sarclisa combined with the reference Pd regimen, improves responses and long-term outcomes, compared with the Pd regimen alone, in patients.

For example, in the pivotal ICARIA-MM Phase III trial, the Sarclisa-Pd combination significantly reduced the risk of disease progression or death by 40%, and improved overall clinically significant survival by 6.9 months.

Sarclisa-Pd is recommended for the management of this category of patients in the treatment guidelines of the Chinese Society of Clinical Oncology and the Chinese Cancer Association, Sanofi adds.


Copyright (c) 2025 CercleFinance.com. All rights reserved.